BOOM
Citations are updated once a week. Recently added citations may not appear.
| Context | Citation |
|---|---|
| Probiotic Mixture 2 {Vetafarm Probotic} - Akkermansia |
📓
Enterococcus faecium GEFA01 alleviates hypercholesterolemia by promoting reverse cholesterol transportation via modulating the gut microbiota-SCFA axis. Frontiers in nutrition (Front Nutr ) Vol: 9 Issue Pages: 1020734 Pub: 2022 Epub: 2022 Nov 8 Authors Xu W , Zou K , Zhan Y , Cai Y , Zhang Z , Tao X , Qiu L , Wei H , Html Article Publication |
| Probiotic Mixture 2 {Vetafarm Probotic} - Akkermansia |
📓
Lactobacillus delbrueckii might lower serum triglyceride levels via colonic microbiota modulation and SCFA-mediated fat metabolism in parenteral tissues of growing-finishing pigs. Frontiers in veterinary science (Front Vet Sci ) Vol: 9 Issue Pages: 982349 Pub: 2022 Epub: 2022 Sep 29 Authors Hou G , Yin J , Wei L , Li R , Peng W , Yuan Y , Huang X , Yin Y , Html Article Publication |
| Probiotic Mixture 2 {Vetafarm Probotic} - Akkermansia |
📓
Enterococcus faecium R0026 combined with Bacillus subtilis R0179 prevent obesity-associated hyperlipidaemia and modulate gut microbiota in C57BL/6 mice. Journal of microbiology and biotechnology (J Microbiol Biotechnol ) Vol: Issue Pages: Pub: 2020 Oct 20 Epub: 2020 Oct 20 Authors Huang J , Huang J , Yin T , Lv H , Zhang P , Li H , Publication |
| Probiotic Mixture 2 {Vetafarm Probotic} - Akkermansia |
📓
Effects of Live Combined Bacillus subtilis and Enterococcus faecium on Gut Microbiota Composition in C57BL/6 Mice and in Humans. Frontiers in cellular and infection microbiology (Front Cell Infect Microbiol ) Vol: 12 Issue Pages: 821662 Pub: 2022 Epub: 2022 Feb 10 Authors Pi X , Teng W , Fei D , Zhao G , Liu W , Publication |
| Probiotic Mixture 2 {Vetafarm Probotic} - Akkermansia |
📓
The administration of Enterococcus faecium SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice. Frontiers in microbiology (Front Microbiol ) Vol: 13 Issue Pages: 1054097 Pub: 2022 Epub: 2022 Dec 16 Authors Panattoni A , Calvigioni M , Benvenuti L , D`Antongiovanni V , Pellegrini C , Di Salvo C , Mazzantini D , Celandroni F , Fornai M , Antonioli L , Ghelardi E , Publication |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
